Skip to main content
. 2020 Apr 28;12:2875–2888. doi: 10.2147/CMAR.S238093

Figure 6.

Figure 6

An illustration of how EVO exerts anticancer activity in osteosarcoma cells through the suppressing Wnt/β-catenin signaling pathway.